|
8 Companies |
|
8 Products |
|
8 Products |
|
8 Mechanisms of Action |
|
0 Trials |
|
42 News |
|
- | Trial completion, Trial completion date: 11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=40, Completed, Sponsor: Helsinki University Central Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019
- | Trial completion, Enrollment change: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=63, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2019 Active, not recruiting --> Completed | N=45 --> 63
- | Trial completion, Enrollment change, Trial primary completion date: T2T@PSU: Tweens to Teens Project at Penn State (clinicaltrials.gov) - Jan 8, 2018
P=N/A, N=188, Completed, Sponsor: Penn State University
Active, not recruiting --> Completed | N=45 --> 63 Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013
- | NN1213 / Novo Nordisk
Trial completion: Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=61, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013 Recruiting --> Completed
- | Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Enrollment closed, Trial primary completion date: Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone (clinicaltrials.gov) - Jun 1, 2017
P=N/A, N=13, Active, not recruiting, Sponsor: University of Virginia
Recruiting --> Completed Completed --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2018
- ||| Enrollment change: BEYAZ-PCOS: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (clinicaltrials.gov) - Mar 31, 2017
P4, N=64, Completed, Sponsor: Woman's
Completed --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2018 N=53 --> 64
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion, Trial primary completion date: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 6, 2016
P2, N=8, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=53 --> 64 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016
- Enrollment closed: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=45, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=170, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Phase classification: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Apr 21, 2016
P2, N=8, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015 Phase classification: P1/2 --> P2
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Enrollment closed: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 21, 2015
P1/2, N=8, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Phase classification: P1/2 --> P2 Recruiting --> Active, not recruiting
- Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Trial completion: Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone (clinicaltrials.gov) - Aug 27, 2015
P=N/A, N=13, Completed, Sponsor: University of Virginia
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: 11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Helsinki University Central Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2015
- | Trial completion, Trial primary completion date, HEOR, Cost effectiveness: SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. (clinicaltrials.gov) - Jul 16, 2015
P3, N=200, Completed, Sponsor: Radboud University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2015
- verucerfont (GSK-561679) / GSK
Enrollment change, Trial withdrawal: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 11, 2015
P1, N=0, Withdrawn, Sponsor: Neurocrine Biosciences
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jul 2015 N=15 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - H
N=15 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Oct 2015 --> Feb 2016
- |||| Trial completion, Enrollment change: BEYAZ-PCOS: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (clinicaltrials.gov) - Apr 7, 2015
P4, N=53, Completed, Sponsor: Woman's
Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed | N=75 --> 53
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial primary completion date: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 11, 2015
P1/2, N=8, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed | N=75 --> 53 Trial primary completion date: Dec 2016 --> Jun 2017
- verucerfont (GSK-561679) / GSK
Enrollment open: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 5, 2015
P1, N=15, Recruiting, Sponsor: Neurocrine Biosciences
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | verucerfont (GSK-561679) / GSK
New P1 trial: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jan 29, 2015
P1, N=15, Not yet recruiting, Sponsor: Neurocrine Biosciences
- ||| Enrollment closed, Trial primary completion date: BEYAZ-PCOS: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (clinicaltrials.gov) - Jul 15, 2014
P4, N=75, Active, not recruiting, Sponsor: BC Women's Hospital & Health Centre
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2015
- Enrollment open, Trial primary completion date: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=45, Recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Feb 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Mar 2016
- Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Mar 2016 Trial primary completion date: May 2014 --> Oct 2015
- Xenical (orlistat) / Roche, GSK
Trial completion: OWL-PCOS: Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women (clinicaltrials.gov) - Apr 14, 2014
P2, N=217, Completed, Sponsor: Milton S. Hershey Medical Center
Trial primary completion date: May 2014 --> Oct 2015 Active, not recruiting --> Completed
- | Efmody (hydrocortisone modified release) / Neurocrine
Biomarker, Trial completion: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort (clinicaltrials.gov) - Jan 5, 2014
P2, N=16, Completed, Sponsor: Diurnal Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Enrollment closed: Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone (clinicaltrials.gov) - Dec 8, 2013
P=N/A, N=13, Active, not recruiting, Sponsor: University of Virginia
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Obesity and Clinical Presentation of Hyperandrogenism (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=46, Completed, Sponsor: Taipei Medical University WanFang Hospital
Recruiting --> Active, not recruiting N=100 --> 46
- Trial completion: Presentations of Hyperandrogenic Phenotypes in Taiwanese Women (clinicaltrials.gov) - Sep 10, 2013
P=N/A, N=649, Completed, Sponsor: Taipei Medical University WanFang Hospital
N=100 --> 46 Not yet recruiting --> Completed
- Trial withdrawal: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Not yet recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Recruiting --> Withdrawn N=500 --> 0
- | Enrollment closed, HEOR, Cost effectiveness: SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. (clinicaltrials.gov) - Jul 24, 2013
P3, N=200, Active, not recruiting, Sponsor: Radboud University
N=500 --> 0 Recruiting --> Active, not recruiting
- abiraterone acetate / Generic mfg.
Trial completion: A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency (clinicaltrials.gov) - Jul 7, 2013
P1, N=6, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
New P1/2 trial: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - May 19, 2013
P1/2, N=8, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
- Clinical: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 6, 2013
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Trial completion: Effects of Androgen Administration on Inflammation in Normal Women (clinicaltrials.gov) - Dec 14, 2012
P=N/A, N=25, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Efmody (hydrocortisone modified release) / Neurocrine
Biomarker, New P2 trial: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort (clinicaltrials.gov) - Nov 26, 2012
P2, N=16, Completed, Sponsor: Diurnal Limited
- ||| Trial completion: Clinical Evaluation of NeoPlex4 Assay and NeoPlex System (clinicaltrials.gov) - Aug 15, 2012
P=N/A, N=7462, Completed, Sponsor: Luminex Corporation
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment change: CaHASE: Study of UK Adults With Congenital Adrenal Hyperplasia. (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=25, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Recruiting --> Completed N=200 --> 25
- Trial completion: CaHASE: Study of UK Adults With Congenital Adrenal Hyperplasia. (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=25, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
N=200 --> 25 Active, not recruiting --> Completed
- Enrollment change: Adrenal Vein Sampling International Study (AVIS Study) (clinicaltrials.gov) - Dec 20, 2011
P=N/A, N=2604, Completed, Sponsor: University Hospital Padova
Active, not recruiting --> Completed N=1900 --> 2604
- Trial completion: Adrenal Vein Sampling International Study (AVIS Study) (clinicaltrials.gov) - Dec 20, 2011
P=N/A, N=2604, Completed, Sponsor: University Hospital Padova
N=1900 --> 2604 Active, not recruiting --> Completed
- abiraterone acetate / Generic mfg.
New P1 trial: A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency (clinicaltrials.gov) - Dec 18, 2011
P1, N=6, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Trial completion: Obesity and Clinical Presentation of Hyperandrogenism (clinicaltrials.gov) - Oct 10, 2011
P=N/A, N=46, Completed, Sponsor: Taipei Medical University WanFang Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Enrollment open: BEYAZ-PCOS: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (clinicaltrials.gov) - Aug 24, 2011
P4, N=75, Recruiting, Sponsor: BC Women's Hospital & Health Centre
Recruiting --> Completed Not yet recruiting --> Recruiting